Estrogen receptor β expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naïve prostate cancer and are elevated in castration-resistant disease

Endocrine-Related Cancer

Volumn 20, Issue 3, 2013, Pages 403-413

  Zellweger, Tobias ^a   Stürm, Susanne ^b   Rey, Silvia ^b   Zlobec, Inti ^c   Gsponer, Joel R ^b   Rentsch, Cyrill A ^b,d   Terracciano, Luigi M ^b   Bachmann, Alexander ^d   Bubendorf, Lukas ^b   Ruiz, Christian ^b  

^a St Claraspital ^*  (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Androgen receptor; Castration resistance; Estrogen receptor; Hormone na ve; Hormone receptors; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR BETA;

ABLATION THERAPY; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; FOLLOW UP; GENE AMPLIFICATION; GENE DOSAGE; GLEASON SCORE; HUMAN; HUMAN TISSUE; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT OUTCOME;

ANDROGEN RECEPTOR; CASTRATION RESISTANCE; ESTROGEN RECEPTOR; HORMONE NAÏVE; HORMONE RECEPTORS; PROSTATE CANCER;

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HUMANS; MALE; PHOSPHORYLATION; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TISSUE ARRAY ANALYSIS;

EID: 84879487288     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0402     Document Type: Article

References (40)

1. Anbalagan M, Huderson B, Murphy L & Rowan BG 2012 Post-translational modifications of nuclear receptors and human disease. Nuclear Receptor Signaling 10 e001.
2. Bonkhoff H & Berges R 2009 The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. European Urology 55 533-542. (doi:10.1016/j.eururo.2008.10.035)
3. Bonkhoff H, Fixemer T, Hunsicker I & Remberger K 1999 Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. American Journal of Pathology 155 641-647. (doi:10.1016/S0002-9440(10)65160-7)
4. Brinkmann AO, Blok LJ, de Ruiter PE, Doesburg P, Steketee K, Berrevoets CA & Trapman J 1999 Mechanisms of androgen receptor activation and function. Journal of Steroid Biochemistry and Molecular Biology 69 307-313. (doi:10.1016/S0960-0760(99)00049-7)
5. Carruba G 2007 Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. Journal of Cellular Biochemistry 102 899-911. (doi:10.1002/jcb.21529)
6. Celhay O, Yacoub M, Irani J, Dore B, Cussenot O & Fromont G 2010 Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression. Journal of Urology 184 2172-2178. (doi:10.1016/j.juro.2010.06.089)
7. Cox RL & Crawford ED 1995 Estrogens in the treatment of prostate cancer. Journal of Urology 154 1991-1998. (doi:10.1016/S0022-5347(01) 66670-9)
8. Culig Z 2004 Androgen receptor cross-talk with cell signalling pathways. Growth Factors 22 179-184. (doi:10.1080/08977190412331279908)
9. Donovan MJ, Hamann S, Clayton M, Khan FM, Sapir M, Bayer-Zubek V, Fernandez G, Mesa-Tejada R, Teverovskiy M, Reuter VE et al. 2008 Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. Journal of Clinical Oncology 26 3923-3929. (doi:10.1200/JCO.2007.15.3155)
10. Donovan MJ, Osman I, Khan FM, Vengrenyuk Y, Capodieci P, Koscuiszka M, Anand A, Cordon-Cardo C, Costa J & Scher HI 2010 Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU International 105 462-467. (doi:10.1111/j.1464-410X.2009.08747.x)
11. Edwards J & Bartlett JM 2005 The androgen receptor and signaltransduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways. BJU International 95 1327-1335. (doi:10.1111/j.1464-410X.2005.05527.x)
12. Feldman BJ & Feldman D 2001 The development of androgen-independent prostate cancer. Nature Reviews. Cancer 1 34-45. (doi:10.1038/35094009)
13. Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, Nesheiwat I, Kong X, Melamed J, Handratta VD et al. 2006 Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10 309-319. (doi:10.1016/j.ccr. 2006.08.021)
14. Hodgson MC, Bowden WA & Agoulnik IU 2012 Androgen receptor footprint on the way to prostate cancer progression. World Journal of Urology 30 279-285. (doi:10.1007/s00345-011-0743-7)
15. Huggins C & Hodges CV 1972 Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA: A Cancer Journal for Clinicians 22 232-240. (doi:10.3322/canjclin.22.4.232)
16. Jemal A, Bray F, Center MM, Ferlay J, Ward E & Forman D 2011 Global cancer statistics. CA: A Cancer Journal for Clinicians 61 69-90. (doi:10.3322/caac.20107)
17. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schroder FH & van Steenbrugge GJ 2000 Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Cancer Research 60 741-748.
18. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T et al. 1997 Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Research 57 314-319.
19. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G & Kallioniemi OP 1998 Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Medicine 4 844-847. (doi:10.1038/nm0798-844)
20. Latil A, Bieche I, Vidaud D, Lidereau R, Berthon P, Cussenot O & Vidaud M 2001 Evaluation of androgen, estrogen (ERα and ERβ), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Research 61 1919-1926.
21. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, Singh H & Ho SM 2001 Comparative studies of the estrogen receptors b and a and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. American Journal of Pathology 159 79-92. (doi:10.1016/S0002-9440(10)61676-8)
22. Lin HK, Hu YC, Yang L, Altuwaijri S, Chen YT, Kang HY & Chang C 2003 Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. Journal of Biological Chemistry 278 50902-50907. (doi:10.1074/jbc.M300676200)
23. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL & Visakorpi T 2001 Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Research 61 3550-3555.
24. MacKenzie L, McCall P, Hatziieremia S, Catlow J, Adams C, McArdle P, Seywright M, Tanahill C, Paul A, Underwood M et al. 2012 Nuclear factor kappaB predicts poor outcome in patients with hormone-naive prostate cancer with high nuclear androgen receptor. Human Pathology 43 1491-1500. (doi:10.1016/j.humpath. 2011.11.009)
25. Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti CA, Gouvin LM, Sharma VM & Mercurio AM 2010 ERβ impedes prostate cancer EMT by destabilizing HIF-1α and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 17 319-332. (doi:10.1016/j.ccr. 2010.02.030)
26. McCall P, Gemmell LK, Mukherjee R, Bartlett JM & Edwards J 2008 Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. British Journal of Cancer 98 1094-1101. (doi:10.1038/sj.bjc.6604152)
27. Nakamura Y, Felizola SJ, Kurotaki Y, Fujishima F, McNamara KM, Suzuki T, Arai Y & Sasano H 2012 Cyclin D1 (CCND1) expression is involved in estrogen receptor b (ERβ) in human prostate cancer. Prostate 73 590-595. (doi:10.1002/pros.22599)
28. Nanni S, Benvenuti V, Grasselli A, Priolo C, Aiello A, Mattiussi S, Colussi C, Lirangi V, Illi B, D'Eletto M et al. 2009 Endothelial NOS, estrogen receptor b, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. Journal of Clinical Investigation 119 1093-1108. (doi:10.1172/JCI35079)
29. Nelles JL, Hu WY & Prins GS 2011 Estrogen action and prostate cancer. Expert Review of Endocrinology & Metabolism 6 437-451. (doi:10.1586/eem.11. 20)
30. Rochette-Egly C 2003 Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cellular Signalling 15 355-366. (doi:10.1016/S0898-6568(02)00115-8)
31. Ruiz C, Seibt S, Al Kuraya K, Siraj AK, Mirlacher M, Schraml P, Maurer R, Spichtin H, Torhorst J, Popovska S et al. 2006 Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. International Journal of Cancer 118 2190-2194. (doi:10.1002/ijc. 21581)
32. Ruiz C, Holz DR, Oeggerli M, Schneider S, Gonzales IM, Kiefer JM, Zellweger T, Bachmann A, Koivisto PA, Helin HJ et al. 2011 Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer. Journal of Pathology 223 543-552. (doi:10.1002/path.2828)
33. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN & Balk SP 1995 Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. New England Journal of Medicine 332 1393-1398. (doi:10.1056/NEJM199505253322101)
34. Urbanucci A, Sahu B, Seppala J, Larjo A, Latonen LM, Waltering KK, Tammela TL, Vessella RL, Lahdesmaki H, Janne OA et al. 2012 Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. Oncogene 31 2153-2163. (doi:10.1038/onc.2011.401)
35. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J & Kallioniemi OP 1995 In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genetics 9 401-406. (doi:10.1038/ng0495-401)
36. Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Janne OA & Visakorpi T 2009 Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Research 69 8141-8149. (doi:10.1158/0008-5472.CAN-09-0919)
37. Wilding G, Chen M & Gelmann EP 1989 Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 14 103-115. (doi:10.1002/pros.2990140204)
38. Wright ME, Tsai MJ & Aebersold R 2003 Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Molecular Endocrinology 17 1726-1737. (doi:10.1210/me.2003-0031)
39. Yuan TC, Veeramani S, Lin FF, Kondrikou D, Zelivianski S, Igawa T, Karan D, Batra SK & Lin MF 2006 Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocrine-Related Cancer 13 151-167. (doi:10.1677/erc.1. 01043)
40. Zellweger T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC, Mihatsch MJ, Gelmann EP & Bubendorf L 2003 Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 55 20-29. (doi:10.1002/pros.10209)